BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for imp...BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.展开更多
目的观察结直肠癌患者脾多肽注射联合FOLFOX4方案化疗治疗效果。方法选取120例结直肠癌患者,据随机数字表法将改其分为观察组与对照组各60例。对照组采取FOLFOX4方案进行全身化疗,观察组在对照组基础上联合脾多肽注射液进行全身化疗,将2...目的观察结直肠癌患者脾多肽注射联合FOLFOX4方案化疗治疗效果。方法选取120例结直肠癌患者,据随机数字表法将改其分为观察组与对照组各60例。对照组采取FOLFOX4方案进行全身化疗,观察组在对照组基础上联合脾多肽注射液进行全身化疗,将250 m L的0.9%氯化钠注射液、6 m L的脾多肽注射液进行静滴,1次/d,连续10 d,14 d为1个周期,连续3个月。观察两组患者的临床疗效、治疗前与治疗后3个月免疫功能、血清miR-21、miR-103、miR-200b水平及不良反应。结果观察组与对照组临床治疗有效率分别为53.3%、33.3%,两组比较差异有统计学意义(χ~2=4.887,P<0.05)。观察组治疗后CD3^-、CD4^-、CD4^-/CD8^-、NK水平与治疗前相比差异无统计学意义(P>0.05),而对照组治疗后上述免疫功能指标低于治疗前(P均<0.05),治疗3个月后观察组上述免疫功能指标与对照组相比差异有统计学意义(P均<0.05)。治疗3个月后,观察组血清miR-21、miR-103水平低于对照组,miR-200b水平高于对照组,差异均有统计意义(P均<0.05)。观察组、对照组骨髓抑制发生率分别为3.3%、8.3%,两组比较差异有统计学意义(P<0.05)。结论脾多肽注射液联合FOLFOX4方案化疗不仅可提高患者的免疫功能,加强对肿瘤细胞的杀伤力,还能降低血清miR-21、miR-103水平,提高miR-200b水平。展开更多
文摘BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.
文摘目的观察结直肠癌患者脾多肽注射联合FOLFOX4方案化疗治疗效果。方法选取120例结直肠癌患者,据随机数字表法将改其分为观察组与对照组各60例。对照组采取FOLFOX4方案进行全身化疗,观察组在对照组基础上联合脾多肽注射液进行全身化疗,将250 m L的0.9%氯化钠注射液、6 m L的脾多肽注射液进行静滴,1次/d,连续10 d,14 d为1个周期,连续3个月。观察两组患者的临床疗效、治疗前与治疗后3个月免疫功能、血清miR-21、miR-103、miR-200b水平及不良反应。结果观察组与对照组临床治疗有效率分别为53.3%、33.3%,两组比较差异有统计学意义(χ~2=4.887,P<0.05)。观察组治疗后CD3^-、CD4^-、CD4^-/CD8^-、NK水平与治疗前相比差异无统计学意义(P>0.05),而对照组治疗后上述免疫功能指标低于治疗前(P均<0.05),治疗3个月后观察组上述免疫功能指标与对照组相比差异有统计学意义(P均<0.05)。治疗3个月后,观察组血清miR-21、miR-103水平低于对照组,miR-200b水平高于对照组,差异均有统计意义(P均<0.05)。观察组、对照组骨髓抑制发生率分别为3.3%、8.3%,两组比较差异有统计学意义(P<0.05)。结论脾多肽注射液联合FOLFOX4方案化疗不仅可提高患者的免疫功能,加强对肿瘤细胞的杀伤力,还能降低血清miR-21、miR-103水平,提高miR-200b水平。
